Karuna Therapeutics Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

BOSTON--()--Karuna Therapeutics, Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.

Contacts

Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
+1 339 970-2843
chris.brinzey@westwicke.com

Media Contact:
Amanda Sellers
GlobalHealthPR
+1 404 865-3597
asellers@globalhealthpr.com

Social Media Profiles

Contacts

Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
+1 339 970-2843
chris.brinzey@westwicke.com

Media Contact:
Amanda Sellers
GlobalHealthPR
+1 404 865-3597
asellers@globalhealthpr.com